Pfanstiehl

Waukegan, United States Founded: 1919 • Age: 107 yrs Acquired By Med Opportunity Partners
APIs, injectable excipients, and bioprocessing solutions are manufactured.
Request Access

About Pfanstiehl

Pfanstiehl is a company based in Waukegan (United States) founded in 1919 was acquired by Med Opportunity Partners in April 2013.. Pfanstiehl has raised $6.7 million across 1 funding round from investors including Fidus Investment and Med Opportunity Partners. Pfanstiehl offers products and services including Sucrose, Trehalose, L-Arginine, and Custom API Manufacturing. Pfanstiehl operates in a competitive market with competitors including Colorcon, SPI Pharma, Scope Ingredients, Meggle Pharma and Crest Cellulose, among others.

  • Headquarter Waukegan, United States
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Pfanstiehl, Inc.
Operational Areas
Healthcare → Healthcare Services & Infrastructure
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $6.7 M (USD)

    in 1 rounds

  • Latest Funding Round
    $6.7 M (USD), Series A

    Jun 01, 2013

  • Investors
  • Employee Count
    Employee Count
  • Acquired by
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Pfanstiehl

Pfanstiehl offers a comprehensive portfolio of products and services, including Sucrose, Trehalose, L-Arginine, and Custom API Manufacturing. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

High-purity stabilizer for vaccines and biologics.

Used for protein aggregation reduction in formulations.

Aids in viscosity reduction for high-concentration biologics.

Provides tailored manufacturing for pharmaceutical needs.

People of Pfanstiehl
Headcount 50-200
Employee Profiles 18
Employee Profiles
People
Vijay Anand Velmurugan
Automation Engineer
People
David Schaad
Director Of Research And Development
People
Hem Sunder Reddy
Director-asia Pacific
People
Jason Martin
Global Director Of Marketing & Americas Business Development

Unlock access to complete

Funding Insights of Pfanstiehl

Pfanstiehl has successfully raised a total of $6.7M through 1 strategic funding round. The most recent funding activity was a Series A round of $6.7 million completed in June 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Series A — $6.7M
  • First Round

    (01 Jun 2013)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2013 Amount Series A - Pfanstiehl Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Pfanstiehl

Pfanstiehl has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Fidus Investment and Med Opportunity Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
PE firm investing in the US
Founded Year Domain Location
-
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Pfanstiehl

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Pfanstiehl

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Pfanstiehl Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Pfanstiehl

Pfanstiehl operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Colorcon, SPI Pharma, Scope Ingredients, Meggle Pharma and Crest Cellulose, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of specialty excipients and corporate-backed venture capital fund focused on healthcare startups
domain founded_year HQ Location
Excipient products and formulations are manufactured for pharmaceutical uses.
domain founded_year HQ Location
Formulations, warehousing, and logistics services for pharmaceuticals are provided.
domain founded_year HQ Location
Develops and manufactures pharmaceutical excipients for the industry.
domain founded_year HQ Location
Pharmaceutical excipients and food ingredients are developed and manufactured.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Pfanstiehl

Pfanstiehl Launches New cGMP
Biospectrumindia5 years ago

Frequently Asked Questions about Pfanstiehl

When was Pfanstiehl founded?

Pfanstiehl was founded in 1919 and raised its 1st funding round 94 years after it was founded.

Where is Pfanstiehl located?

Pfanstiehl is headquartered in Waukegan, United States. It is registered at Waukegan, Illinois, United States.

Is Pfanstiehl a funded company?

Pfanstiehl is a funded company, having raised a total of $6.7M across 1 funding round to date. The company's 1st funding round was a Series A of $6.7M, raised on Jun 01, 2013.

What does Pfanstiehl do?

Founded in 1919, Pfanstiehl operates as a CDMO in the pharmaceutical and biopharmaceutical sectors from Waukegan, United States. Injectable formulation ingredients, pharmaceutical intermediates, and APIs are developed and produced in quantities from grams to multi-tons. GMP services encompass API and HPAPI manufacturing, advanced intermediates, potent compounds, linker-toxins for ADCs, and nucleoside chemistry. Biopharma offerings include carbohydrate chemistry, protein stabilizers, parenteral excipients, bioprocessing components, solubilizers, vaccine stabilizers, and lyoprotectants.

Who are the top competitors of Pfanstiehl?

Pfanstiehl's top competitors include Colorcon, DFE Pharma and Crest Cellulose.

What products or services does Pfanstiehl offer?

Pfanstiehl offers Sucrose, Trehalose, L-Arginine, and Custom API Manufacturing.

Who are Pfanstiehl's investors?

Pfanstiehl has 2 investors. Key investors include Fidus Investment, and Med Opportunity Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available